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Transhepatic radionuclide infusion has been introduced as a new treatment approach for
unresectable liver neuroendocrine metastatic lesions with the prerequisite of a positive
In-111 Pentetreotide (Octreoscan). Patients with multiple liver neuroendocrine metastases
can be locally treated after selective hepatic artery catheterization and infusion of radiola-
beled somatostatin analogs, and in case of extra-hepatic secondary spread, after simple
i.v. application. According to the world wide references, the average dose per session to
each patient is 6.3±0.3GBq (∼160–180mCi) of In-111-DTPA-Phe1-Pentetreotide, 10- to
12-fold in total, administered monthly or of 4.1±0.2GBq (∼105–116mCi) of Y-90 DOTA
TOC, threefold in total, or of 7 .0±0.4GBq (∼178–200mCi) of Lu-177 DOTATATE, fourfold
to sixfold in total (the choice of which being based on the tumor size, assessed by CT or
MRI). Follow-up at monthly intervals has to be performed by means of ultrasonography
(US). Treatment response has to be assessed according to the WHO criteria (RECIST or
SWOG).
Keywords: radiopeptide therapy, neuroendocrine tumors, Y-90 DOTA TOC Lu-177 DOTA TATE, In-111-DTPA-Phe1-
pentetreotide
INTRODUCTION
On the course of the development from a normal cell to a can-
cer one the overexpression of surface receptors consists a very
important characteristic among a plethora of morpho-functional
changes of these cells. This receptor overexpression provides the
possibility to be used as a target site of corresponding peptides
which, if appropriately radiolabeled, can be used for imaging and
further shifting to treating purposes.
Thetherapeuticimplementationof theradiolabeledpeptidesis
based on: (i) their proven internalization into the cytoplasma and
consequently (ii) their tight approach to the nucleus, in striking
distance from the chromosomes, with DNA being the fatal target
within the radiomolecular emission range (a necessary and oblig-
atory assumption for the certain chromosomal destroy;Anderson
et al.,1996; Tiensuu Janson et al., 2000; Buchegger et al.,2006).
THE CONCEPT
Since the discovery in the late 1970s by Guillemin of native
tetradeca-peptide somatostatin (Guillemin and Gerich, 1976),
ﬁve speciﬁc receptor subtypes have been discovered and cloned
(Hoyer et al., 1995). However, their extremely short plasma half-
life(<3min)inspiredthesynthesisofanalogswithmorefavorable
characteristics,that means a longer half-life and a marked smaller
molecule. First synthetic analog of tetradeca-peptide somato-
statin used to be octreotide, containing the bioactive core of the
native molecule, which consists of eight amino-acids. Octreotide
binds with relative high afﬁnity (22±3.6nM) only to subtype II
somatostatin receptors whereas with a lower one to subtypes III
(182±13nM) and V (237±52nM; Reubi et al., 2000; Schmitt
etal.,2001).Labeledwithindium-111(Octreoscan,Mallinckrodt,
Petten,The Netherlands) it has been established as the radiophar-
maceutical of choice for selective imaging of tissues and lesions
positive mainly for somatostatin subtype II receptors. After i.v.
application, Octreoscan is internalized into the tumor-cell by
ﬂuid-phase endocytosis, and degraded in two insoluble metabo-
lites In-111 DTPA-d-Phe-Cys-OH and In-111 DTPA-d-Phe-OH
(Anderson et al., 1996; De Jong et al., 1997; Bass et al., 1998)
inside the lysosomes,close to the nucleus,where they are retained
(De Jong et al., 1998; Janson et al., 2000). Thereafter, the empty
receptor drives again to the cell membrane surface. Subsequently,
the use of Octreoscan was extended with success for therapeutic
purposes too, in particular for the confrontation of unresectable
neuroendocrine tumors (i) due to the high efﬂux of indium-111
Auger and Internal Conversion electrons and (ii) the extremely
high radioactive ratio of the tumor vs. the healthy peri-tumoral
tissue (approximately 30:1).
THE TUMOR CONFRONTATION
First, in 1993, high doses of In-111-DTPA-Phe1-octreotide were
used for the treatment of these type of tumors (Krenning et al.,
1993, 1994) via antecubital intravenous infusions, exploiting the
Auger (0.02–10μm particle range),and Internal Conversion elec-
tron emission (200–550μm particle range) of indium-111 (Adel-
stein, 1993; Krenning et al., 1993, 1994). However, because of
the too small particle range and therefore the lower tissue pen-
etration, 111In-labeled peptides could not be the considered as
the ideal radiopharmaceutical for peptide receptor radionuclide
therapy (PRRT) and their use were monitored for liver metasta-
sized tumors of smaller than 20mm diameter, and strictly intra-
arterially, after catheterization of the hepatic artery (Limouris
et al., 2008). This application way is directly related to the rhe-
ology of the administration route, as the distance between the
point of the i.a. infusion (the femoral artery) up to the hepatic
artery/feeding tumor arterial net (ﬁrst pass extraction) is short,
and promptly trapped by the tumor somatostatin receptors,over-
passingtherenalarteries.Thisisincontrastwiththelongdistance
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venous way (antecubital up to the pulmonary vein net) in case
of i.v. implementation. The aforementioned result in a maximiza-
tion of the absorbed activity rate onto the metastatic liver lesions
compared to that calculated after an i.v. infusion, achieving a
larger tumor burden with the lowest possible delivered dose to
the kidneys (Limouris et al.,1999,2008).
In the late 1990s, intensive work and investigations in
radiochemistry considered yttrium-90 to be more suitable and
effective for therapeutic use compared to indium-111 because
of its energetic β-particles (Emax =2.27MeV) and long range
[R95 =5.94mm (R95 being the distance within which the β-
particle transfers 95% of its energy to the target tissue)] which
allows “cross-ﬁre” irradiation (Paganelli et al., 2001). Coupled
with DOTA chelator,binds with an afﬁnity of 11±1.7,389±135,
and 114±29nM to subtype II, III, and V somatostatin receptors
respectively (Reubi et al., 2000; Schmitt et al., 2001). Radiothera-
peutic use of Y-90DOTATOC leads to a higher and more evenly
distributed radiation dose to the tumor because of its larger parti-
clerange(Rmax:11mm)andtissuepenetration.Tumorswithanin
homogeneousdistributionof receptorsseemtorespondfavorably
to PRRT treatments with Y-90 DOTATOC (De Jong et al., 1997;
Paganelli et al.,2001; Bodei et al.,2004).
However, the use of yttrium-90 did not fully satisfy the thera-
pists involved in the treatments of neuroendocrine malignancies
due to the lack of γ emission that highly facilitates the dosimetric
work. The scientiﬁc efforts and pursuances lead to the develop-
ment of a third generation radiopeptides, labeled with a longer
half-lifeandaγ emissionnuclideasisthecasewithLu-177DOTA
TATE. With a Eβ max of 0.497MeV, a Eγ of 113KeV (6.4%),
and 208KeV (11.0%) a penetration range of 2mm and a 6.7-days
half-life Lu-177 DOTA TATE binds with an afﬁnity of 1.5±0.4,
453±176,and547±160nMtosubtypeII,III,andVsomatostatin
receptorsrespectively(Reubietal.,2000;Kwekkeboometal.,2001,
2003, 2005; Schmitt et al.,2001; Seregni et al., 2010)( Figure 1).
The treatment of liver neuroendocrine metastases is still a
major doctor’s dilemma because the majority of patients present
with extensive unresectable disease. Apart from surgical resec-
tion which is the treatment of choice, systemic therapy, hepatic
artery(chemo-)embo-lization,andradiofrequencyablationclaim
proved clinical beneﬁt. Patients,objective to surgery with curative
intention are few,and a complete resection still show a low (30%)
overall survival rate. In systemic therapy the use of intravenous
chemotherapy is not leading to the best expected results due to
the diverse variables, including type of chemotherapy, stage of
disease, progression, and toxicity. In our Institution the concept
of isolated liver radionuclide perfusion was ﬁrstly developed in
an hepatoma case, were In-111 labeled somatostatin, after selec-
tive catheterization of the hepatic artery, was injected (Limouris
et al., 1998, 1999). Thus, by this way, a markedly higher radi-
ation amount within the liver nodule can be deposited and in
FIGURE 1 | Radiomolecular combined therapy of multiple liver metastases originated from a resected pancreatic neuroendocrine tumor treated with
high doses of (A). In-111 Pentetreotide and (B) Lu-177 DOTATATE.
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parallel with the lowest possible, extra-tumoral radiobiological
burden mainly, in regard to the kidneys (critical organ). Purpose
ofthisaforementionedadministrationprocedurewastointroduce
transhepatic radionuclide infusion (THRI) as a treatment option
modality for unresectable, multiple, small, or moderate in size,
liver metastases, routinely, along with a nephroprotective scheme
comprising amino-acid solution (1000mL), fallowed by 50mg
DTPA in 250mL normal saline,in drip infusion (“The Aretaieion
Protocol”).
NON-RADIOMOLECULAR TREATMENT OPTIONS
From the pharetra of loco-regional ablation techniques,
cryosurgery is an open abdominal surgery procedure with risks
and complications, needing special equipment with cryoprobes
working by means of supercooled liquid nitrogen and argon gas.
(Chemo-) embo-lization and percutaneous radiofrequency abla-
tion are two minimally invasive procedures which compared to
cryotherapy, are usually done in a conventional radiology unit.
For the latter two, the number of liver lesions under treatment
should be less than 3, a prerequisite not to be ignored, since the
majority of the neuroendocrine liver metastases are multiple.
PERSPECTIVES
Transhepatic radionuclide infusion presents a new viewpoint on
an important area of research, aiming to consist the treating
modality of preference for the confrontation of unresectable neu-
roendocrine malignancies. Comparing and evaluating the world-
wide experience of the rather few international centers of excel-
lence, routinely dealing with radiopeptide therapy, the following
perspectives might optimize their application.
IMPLEMENTATION IN COCKTAILS
Applied in combination (i.e., indium-111/lutetium-177 or
yttrium-90/lutetium-177) and exploiting the different radionu-
clide emission ranges, irradiating the tumor-cell in different loci
from the point of their uptake (receptors), they increase their
destruction capability (Limouris et al.,2008; Seregni et al., 2010).
INTRA-ARTERIAL VS. INTRAVENOUS APPLICATION
Where the i.a. way is possible (liver or brain lesions) it has to
be preferred because the amount of the tumor absorbed dose is
higher. This happens because the radiopharmaceutical covers a
much longer distance to reach the target-organ (tumor DNA),
initiating the radiopeptide infusion after venous catheterization,
since an important part of it, is taken up from the traversing
tissues. Such tissues are the kidneys which for the THRI con-
sist the critical organ. It is proved (Kontogeorgakos et al., 2006;
Limouris et al., 2008) that the kidney biological burden is in
a more than 40% decreased compared to that calculated in i.v.
infusions.
THRI BEFORE SURGICAL EXERESIS
Large volume neuroendocrine tumors over 6cm in diameter
(aboutmorethan60g)isextremelydifﬁculttobemanaged.Their
treatmentinitializationwithsurgicalexcisionlurksapotentialdis-
semination tumor-cell-spread. On the contrary,THRI alone,can-
notprovidethenecessaryabsorbeddosetotheminordertoobtain
a satisfactory response (partial or complete) due to (i) the recep-
tor heterogeneity of the large lesions, not achieving the expected
high absorbed doses and (ii) the kidney radiobiological overbur-
den, rendering in a mass, as forbidden, for any further treatment
continuation. Conventional intravenous therapy regarding large
volume tumors is doubtless insufﬁcient. Therefore, initializing
the treatment course by means of 3–4 cycles of THRI, prior to
the surgical excision, the dissemination danger can be potently
minimized and the forthcoming surgical intervention more safely
implemented.
Finally,itwouldbeanomissiontonotreportondataregarding
the time interval between the initialization of a given treatment
up to any regression time observed to the treated tumors, i.e.,
theprogression-freesurvival(PFS),consideringtheneuroendocrine
diseaseasachronicillness.InstudiesbyKwekkeboometal.(2008)
with Lu-177 DOTA TATE, the median PFS was 40months. In
studies by Cwikla with Y-90-DOTA TATE, the median PFS was
17months, whereas in studies by Valkema with Y-90 DOTATOC
the median PFS was reported to be 30months (Valkema et al.,
2003; Cwikla et al.,2010).
Newer strategies to augment the therapeutic potential
of PRRT in combination with radiosensitizing chemother-
apy or biomolecular targeted agents, are so far under
investigation.
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